Real World Oncology in China
You Have Questions.
We Get Answers.
Since 2015, GenomiCare has been a pioneer in guiding patient-centered precision medical care for Chinese cancer patients through direct patient engagement, complete genomic profiling, and close collaboration with physicians and hospitals.
GenomiCare Biotechnology provides pharmaceutical and biotech companies with real world insights into key differences in cancer treatment and disease management in China, enabling both their research and commercial programs.
Across China, we partner with 1,200+ leading physicians and 200+ hospitals, including a unique partnership with Jiahui hospital in Shanghai, and its collaborating US counterpart Massachusetts General Hospital.
Longitudinal Real World Data Integration
We collect and curate consented, longitudinal clinical data on each of our patients across multiple institutions, and combine these data with state-of-the-art genomics data.
Prospective Cohort Expansion
Sponsor-directed cohort expansions using our extensive clinical network
Fully integrated expert curation of clinical and molecular data
Dynamic real-time cohort analysis
AI-driven real time analysis generating real time analysis
Fully compliant, secured portal access for real-time analysis